Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 5/9/2005 First Published: 2/20/2004


1.		Phase III Randomized Study of TLK286 Versus Doxorubicin HCl Liposome or Topotecan as Third-Line Therapy in Patients With Platinum-Refractory or -Resistant Metastatic Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-03087 TLK-286.3017, NCT00078884


2.		Study of TLK286 (Telcyta) vs. Gefitinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.3020 NCT00080340


3.		TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.3024 NCT00102973


4.		Ph 3 Randomized Study of Telcyta® + Liposomal Doxorubicin Vs Liposomal Doxorubicin in Platinum Refractory or Resistant Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				Pharmaceutical / Industry				TLK286.3025 NCT00350948

Last Modified: 12/31/2003 First Published: 8/24/2003


5.		Phase I/II Study of TLK286 and Docetaxel in Patients With Stage IIIB or IV Platinum-Resistant Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				UCLA-0302051 TLK-286.2012, NCT00068705


6.		TLK286 in Combination With Paraplatin (Carboplatin) in Recurrent Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.2018 NCT00051948


7.		TLK286 in Combination With Doxil in Platinum Refractory or Resistant Ovarian Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.2011 NCT00052065


8.		TLK286 (Telcyta) in Combination With Cisplatin for Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				TLK286.2021 NCT00077883


9.		Carboplatin, Paclitaxel and TLK286 (Telcyta) as First-Line Therapy in Advanced Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Closed				18 and over				Pharmaceutical / Industry				TLK286.2023 NCT00088556

Last Modified: 8/8/2007 First Published: 8/1/2001


10.		Phase II Study of TLK286 in Patients With Platinum-Resistant Advanced Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI, Pharmaceutical / Industry				MSKCC-01059 TLK-286.2003, NCI-G01-1998, NCT00022347

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute